CClinicalTrials.gg
CompletedNCT03444558Updated Oct 24, 2018

Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors

An interventional study of Natural supplement containing chlorogenic acid and luteolin and Placebo (without any active ingredients) in Metabolic Syndrome, sponsored by University of Palermo. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-24.

Sponsored by University of Palermo · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Clinical trial about beneficial effects of natural ingredient containing chlorogenic acid and luteolin on liver health and conditions related to liver (such as metabolic syndrome) for general body health.

Read the detailed description

This is one randomized, double-blind, placebo-controlled study. The purpose of the present study is to evaluate and/or elucidate the role of the natural supplement, containing chlorogenic acid (10-12%) and luteinyl-7-glucoside (2-4%), on cardio-metabolic risk factors.

The research hypothesis is to evaluate whether natural supplement containing chlorogenic acid and luteolin (Puraltilix, BIONAP SRL, Catania, Italy) may improve several cardio-metabolic parameters in subjects with the metabolic syndrome.

All subjects will be evaluated at baseline and after 6 months of treatment (with natural supplement or placebo).

02

Conditions studied

  • Metabolic Syndrome

Keywords

  • metabolic parameters
  • cardio-metabolic parameters
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men and women aged >18 years with the metabolic syndrome (as defined by the international criteria: Alberti KG, et al. Circulation. 2009; 120: 1640-5);
  • BMI> 25 kg/m\^2;
  • Subjects able to swallow whole tablets;
  • Informed consent obtained prior to any study-related activities.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or willingness to become pregnant;
  • Severe liver dysfunction (ALT >2.5 times upper limit of normal);
  • Severe renal failure (eGFR\<60 mL/min/1.73 m2 using the MDRD formula);
  • Severe infections at the discretion of the investigator (such as HIV, HBV and HCV);
  • History or presence of malignant neoplasms within the last 5 years.
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Dietary Supplement

    50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)

    Dietary Supplement: Natural supplement containing chlorogenic acid and luteolin

  • Placebo comparator
    Placebo

    50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)

    Other: Placebo (without any active ingredients)

Interventions

  • Dietary supplementNatural supplement containing chlorogenic acid and luteolin

    50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

  • OtherPlacebo (without any active ingredients)

    50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

05

What researchers measure

Primary outcomes

  1. Effect of natural supplement on metabolic parameters including body weight and Body Mass Index (BMI)

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including body weight (kg) and height (m) that will be combined to report BMI in kg/m\^2.

    Time frame: Change from baseline to 6 months of the supplementation

  2. Effect of natural supplement on metabolic parameters including waist circumference

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including waist circumference (cm).

    Time frame: Change from baseline to 6 months of the supplementation

  3. Effect of natural supplement on metabolic parameters including plasma lipids

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol HDL-C) (mmol/l), while low-density lipoprotein cholesterol (LDL-C) will be calculated using the Friedewald formula.

    Time frame: Change from baseline to 6 months of the supplementation

  4. Effect of natural supplement on metabolic parameters including glucose metabolism parameters

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma glycemia (mmol/l).

    Time frame: Change from baseline to 6 months of the supplementation

  5. Effect of natural supplement on metabolic parameters including plasma insulinemia and HOMA (homeostatic model assessment) index

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma insulinemia (pmol/L) that with glycemia will be combined to report HOMA index.

    Time frame: Change from baseline to 6 months of the supplementation

Secondary outcomes

  1. Effect of natural supplement on cardio-metabolic parameters including plasma cytokines

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including plasma cytokines (inflammatory markers and adipokines) (pg/ml), that will be assessed using available enzyme-linked immunosorbent assay (ELISA) kits.

    Time frame: Change from baseline to 6 months of the supplementation

  2. Effect of natural supplement on cardio-metabolic parameters including plasma lipoproteins

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including atherogenic lipoproteins as well as the analysis of the full spectrum of lipoprotein subclasses by gel electrophoresis.

    Time frame: Change from baseline to 6 months of the supplementation

  3. Effect of natural supplement on cardio-metabolic parameters including subclinical atherosclerosis

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including subclinical atherosclerosis assessed by carotid intima-media thickness (CIMT) (mm).

    Time frame: Change from baseline to 6 months of the supplementation

  4. Effect of natural supplement on cardio-metabolic parameters including fatty liver index

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including fatty liver index, a noninvasive method used for steatosis detection and quantification.

    Time frame: Change from baseline to 6 months of the supplementation

06

Study locations

1 site
  • University Hospital of Palermo
    Palermo, Palrmo 90127, Italy
07

References and documents

Publications

  • Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5. PubMed 19805654 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03444558
Lead sponsor
University of Palermo
Collaborators
University of Catania
Responsible party
Manfredi Rizzo (MD, PhD, Associate Professor, University of Palermo) — Principal investigator
First posted
Feb 23, 2018
Start date
Jun 1, 2017
Primary completion
Feb 28, 2018
Completion
Feb 28, 2018
Last update
Oct 24, 2018

Study contacts

Manfredi Rizzo, MD, PhD
principal investigator · University Hospital of Palermo, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion